Summary by Moomoo AI
Elevai Labs has executed a 1-for-200 reverse stock split of its common stock effective November 27, 2024. The split was initially approved by the Board of Directors on July 23, 2024, and received stockholder approval on August 12, 2024, with the final ratio determined by the CEO on November 20, 2024.The company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 27, 2024, retaining the trading symbol "ELAB" but under a new CUSIP number (28622K 203). No fractional shares were issued, with stockholders entitled to receive one whole share in lieu of fractional shares.The split had no effect on the stock's par value of $0.0001. The company has adjusted its equity incentive plan, including the number of shares available for future grants, outstanding awards, and exercise prices of stock options to reflect the split's effects.
